Protocol for the phase 2 edelife trial investigating the efficacy and safety of intra-amniotic er004 administration to male subjects with x-linked hypohidrotic ectodermal dysplasia

HIGHLIGHTS

• who: Holm Schneider and colleagues from the Center for Ectodermal Dysplasias and Department Pediatrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nu00fcrnberg, Erlangen, Germany have published the Article: Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia, in the Journal: (JOURNAL)
• what: The aim of the EDELIFE trial is to assess the efficacy of prenatal intraamniotic administrations of ER004 to male subjects with an EDA null mutation in rescuing their ability to perspire at six months of age . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.